Bioventus Stock Cash And Equivalents

BVS Stock

USD 11.71 0.20 1.74%

Bioventus fundamentals help investors to digest information that contributes to Bioventus' financial success or failures. It also enables traders to predict the movement of Bioventus Stock. The fundamental analysis module provides a way to measure Bioventus' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bioventus stock.

Short Long Term Debt Total Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Bioventus Company Cash And Equivalents Analysis

Bioventus' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.

Cash

Bank Deposits

+

Liquidities

More About Cash And Equivalents | All Equity Analysis

Current Bioventus Cash And Equivalents

34.36 M

Most of Bioventus' fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bioventus is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Bioventus Cash And Equivalents Driver Correlations

Understanding the fundamental principles of building solid financial models for Bioventus is extremely important. It helps to project a fair market value of Bioventus Stock properly, considering its historical fundamentals such as Cash And Equivalents. Since Bioventus' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Bioventus' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Bioventus' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Good Will	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Net Tangible Assets	Property Plant Equipment	Long Term Debt	Net Invested Capital	Long Term Investments	Short Long Term Debt	Capital Stock	Net Working Capital	Short Term Investments	Capital Surpluse	Deferred Long Term Liab
Total Assets		0.86	0.17	0.9	-0.22	0.9	0.87	0.11	0.97	0.82	0.65	0.97	-0.66	-0.57	0.71	0.92	0.97	0.43	0.86	-0.89	-0.7	-0.23	-0.23	-0.23
Total Stockholder Equity	0.86		0.44	0.69	0.19	0.58	0.6	0.53	0.72	0.54	0.45	0.79	-0.67	-0.69	0.5	0.7	0.9	0.63	0.52	-0.72	-0.44	-0.08	-0.08	-0.08
Current Deferred Revenue	0.17	0.44		-0.13	0.44	-0.2	0.21	0.85	0.03	0.27	-0.08	-0.03	0.23	0.24	0.24	-0.06	0.22	0.92	-0.06	0.01	0.33	0.36	0.36	0.36
Net Debt	0.9	0.69	-0.13		-0.4	0.94	0.81	-0.11	0.91	0.75	0.72	0.91	-0.77	-0.65	0.66	0.98	0.9	0.16	0.87	-0.93	-0.61	-0.38	-0.38	-0.38
Retained Earnings	-0.22	0.19	0.44	-0.4		-0.46	-0.54	0.73	-0.35	-0.56	-0.42	-0.18	0.14	-0.16	-0.41	-0.47	-0.22	0.28	-0.6	0.52	0.19	0.79	0.79	0.79
Accounts Payable	0.9	0.58	-0.2	0.94	-0.46		0.84	-0.26	0.96	0.78	0.69	0.94	-0.6	-0.5	0.62	0.93	0.83	0.05	0.91	-0.85	-0.8	-0.3	-0.3	-0.3
Net Receivables	0.87	0.6	0.21	0.81	-0.54	0.84		-0.04	0.9	0.99	0.61	0.77	-0.38	-0.16	0.8	0.88	0.86	0.42	0.92	-0.87	-0.51	-0.37	-0.37	-0.37
Good Will	0.11	0.53	0.85	-0.11	0.73	-0.26	-0.04		-0.09	-0.04	-0.17	-0.02	0.06	-0.11	-0.05	-0.12	0.19	0.75	-0.3	0.1	0.34	0.49	0.49	0.49
Total Liab	0.97	0.72	0.03	0.91	-0.35	0.96	0.9	-0.09		0.85	0.67	0.96	-0.59	-0.47	0.72	0.92	0.91	0.28	0.92	-0.87	-0.79	-0.26	-0.26	-0.26
Total Current Assets	0.82	0.54	0.27	0.75	-0.56	0.78	0.99	-0.04	0.85		0.57	0.69	-0.33	-0.07	0.83	0.83	0.81	0.47	0.9	-0.84	-0.43	-0.38	-0.38	-0.38
Short Term Debt	0.65	0.45	-0.08	0.72	-0.42	0.69	0.61	-0.17	0.67	0.57		0.65	-0.61	-0.4	0.65	0.69	0.6	0.15	0.72	-0.67	-0.43	-0.36	-0.36	-0.36
Intangible Assets	0.97	0.79	-0.03	0.91	-0.18	0.94	0.77	-0.02	0.96	0.69	0.65		-0.7	-0.67	0.6	0.9	0.91	0.23	0.83	-0.83	-0.83	-0.18	-0.18	-0.18
Common Stock	-0.66	-0.67	0.23	-0.77	0.14	-0.6	-0.38	0.06	-0.59	-0.33	-0.61	-0.7		0.9	-0.5	-0.75	-0.71	-0.1	-0.59	0.76	0.43	0.46	0.46	0.46
Net Tangible Assets	-0.57	-0.69	0.24	-0.65	-0.16	-0.5	-0.16	-0.11	-0.47	-0.07	-0.4	-0.67	0.9		-0.16	-0.58	-0.61	0.01	-0.32	0.56	0.47	0.2	0.2	0.2
Property Plant Equipment	0.71	0.5	0.24	0.66	-0.41	0.62	0.8	-0.05	0.72	0.83	0.65	0.6	-0.5	-0.16		0.73	0.7	0.48	0.86	-0.74	-0.29	-0.35	-0.35	-0.35
Long Term Debt	0.92	0.7	-0.06	0.98	-0.47	0.93	0.88	-0.12	0.92	0.83	0.69	0.9	-0.75	-0.58	0.73		0.93	0.24	0.92	-0.97	-0.59	-0.47	-0.47	-0.47
Net Invested Capital	0.97	0.9	0.22	0.9	-0.22	0.83	0.86	0.19	0.91	0.81	0.6	0.91	-0.71	-0.61	0.7	0.93		0.48	0.82	-0.94	-0.56	-0.34	-0.34	-0.34
Long Term Investments	0.43	0.63	0.92	0.16	0.28	0.05	0.42	0.75	0.28	0.47	0.15	0.23	-0.1	0.01	0.48	0.24	0.48		0.23	-0.3	0.13	0.14	0.14	0.14
Short Long Term Debt	0.86	0.52	-0.06	0.87	-0.6	0.91	0.92	-0.3	0.92	0.9	0.72	0.83	-0.59	-0.32	0.86	0.92	0.82	0.23		-0.89	-0.64	-0.46	-0.46	-0.46
Capital Stock	-0.89	-0.72	0.01	-0.93	0.52	-0.85	-0.87	0.1	-0.87	-0.84	-0.67	-0.83	0.76	0.56	-0.74	-0.97	-0.94	-0.3	-0.89		0.52	0.61	0.61	0.61
Net Working Capital	-0.7	-0.44	0.33	-0.61	0.19	-0.8	-0.51	0.34	-0.79	-0.43	-0.43	-0.83	0.43	0.47	-0.29	-0.59	-0.56	0.13	-0.64	0.52		0.1	0.1	0.1
Short Term Investments	-0.23	-0.08	0.36	-0.38	0.79	-0.3	-0.37	0.49	-0.26	-0.38	-0.36	-0.18	0.46	0.2	-0.35	-0.47	-0.34	0.14	-0.46	0.61	0.1		1.0	1.0
Capital Surpluse	-0.23	-0.08	0.36	-0.38	0.79	-0.3	-0.37	0.49	-0.26	-0.38	-0.36	-0.18	0.46	0.2	-0.35	-0.47	-0.34	0.14	-0.46	0.61	0.1	1.0		1.0
Deferred Long Term Liab	-0.23	-0.08	0.36	-0.38	0.79	-0.3	-0.37	0.49	-0.26	-0.38	-0.36	-0.18	0.46	0.2	-0.35	-0.47	-0.34	0.14	-0.46	0.61	0.1	1.0	1.0

Click cells to compare fundamentals

Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).

Competition

Predict Bioventus

In accordance with the recently published financial statements, Bioventus has 34.36 M in Cash And Equivalents. This is 95.81% lower than that of the Health Care Equipment & Supplies sector and 93.84% lower than that of the Health Care industry. The cash and equivalents for all United States stocks is 98.73% higher than that of the company.

Bioventus Cash And Equivalents Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bioventus' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bioventus could also be used in its relative valuation, which is a method of valuing Bioventus by comparing valuation metrics of similar companies.

Bioventus is currently under evaluation in cash and equivalents category among its peers.

Bioventus Current Valuation Drivers

We derive many important indicators used in calculating different scores of Bioventus from analyzing Bioventus' financial statements. These drivers represent accounts that assess Bioventus' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Bioventus' important valuation drivers and their relationship over time.

		2019	2020	2021	2022	2023	2024 (projected)
Enterprise Value		1.2B	1.2B	1.2B	546.5M	688.0M	1.2B

Bioventus ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Bioventus' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Bioventus' managers, analysts, and investors.

Environmental

Governance

Social

Bioventus Fundamentals

	Return On Equity	-0.25
	Return On Asset	0.0248
	Profit Margin	(0.07) %
	Operating Margin	0.05 %
	Current Valuation	1.11 B
	Shares Outstanding	65.37 M
	Shares Owned By Insiders	11.47 %
	Shares Owned By Institutions	69.76 %
	Number Of Shares Shorted	1.34 M
	Price To Earning	6.96 X
	Price To Book	5.15 X
	Price To Sales	1.38 X
	Revenue	512.35 M
	Gross Profit	302.71 M
	EBITDA	(23.07 M)
	Net Income	(96.74 M)
	Cash And Equivalents	34.36 M
	Cash Per Share	0.56 X
	Total Debt	394.85 M
	Debt To Equity	1.17 %
	Current Ratio	0.94 X
	Book Value Per Share	2.28 X
	Cash Flow From Operations	15.34 M
	Short Ratio	3.57 X
	Earnings Per Share	(0.61) X
	Price To Earnings To Growth	2.14 X
	Target Price	14.67
	Number Of Employees	1.03 K
	Beta	0.88
	Market Capitalization	765.46 M
	Total Asset	810.91 M
	Retained Earnings	(321.54 M)
	Working Capital	92.5 M
	Net Asset	810.91 M

About Bioventus Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Bioventus's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bioventus using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bioventus based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Bioventus Stock Analysis

When running Bioventus' price analysis, check to measure Bioventus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bioventus is operating at the current time. Most of Bioventus' value examination focuses on studying past and present price action to predict the probability of Bioventus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bioventus' price. Additionally, you may evaluate how the addition of Bioventus to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC